Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 NORTH AMERICA UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 NORTH AMERICA UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 NORTH AMERICA UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 39 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 40 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 41 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 42 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 43 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 44 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 46 NORTH AMERICA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 48 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 49 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 51 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 52 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 53 U.S. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 55 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 56 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 58 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 59 U.S. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 60 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 61 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 62 U.S. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 U.S. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 64 U.S. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 65 U.S. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 66 U.S. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 67 U.S. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 68 U.S. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 69 CANADA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 71 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 72 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 73 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 74 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 75 CANADA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 76 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 77 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 78 CANADA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 CANADA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 CANADA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 CANADA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 82 CANADA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 83 CANADA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 84 CANADA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 85 MEXICO UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 88 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 89 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 90 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)
TABLE 91 MEXICO BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 92 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)
TABLE 94 MEXICO BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 MEXICO SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 96 MEXICO URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 97 MEXICO STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 MEXICO UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)
TABLE 99 MEXICO UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 100 MEXICO UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA UNDERACTIVE BLADDER MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE NORTH AMERICA UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA UNDERACTIVE BLADDER MARKET
FIGURE 14 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
